Cancer is one of the biggest health challenges and the third leading cause of death worldwide. Cervical cancer, after breast cancer, is the most common type of cancer in women in many regions. Research has shown that oncolytic viruses, especially those that do not have humans as hosts, have significant anti-cancer effects. One of the challenges of using these viruses is their rapid clearance by the immune system. Therefore, the use of suitable carriers with anti-tumor affinity for delivering these viruses and enhancing their efficacy is essential. The aim of this study is to investigate the therapeutic effects of dendritic cells carrying Newcastle disease virus on the treatment of a mouse model of cervical cancer induced by papillomavirus. This study was conducted under cell culture conditions and mouse modeling. Forty female C57BL/6 mice weighing 20 to 25 grams and aged 6 to 8 weeks were divided into four groups. The groups included mice that were treated with PBS, doxorubicin, dendritic cells with tumor lysate, and dendritic cells carrying Newcastle disease virus, respectively. After observing palpable tumors, the mice were treated with virus-carrying dendritic cells. The results showed that mice receiving virus-carrying dendritic cells had better survival and slower tumor growth compared to the control group. Additionally, this treatment significantly increased nitric oxide and lactate dehydrogenase production while elevating IFN-γ secretion and reducing IL-4, IL-10, and TGF-β secretion.